Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients [Yahoo! Finance]
Cadrenal Therapeutics, Inc. (CVKD)
Company Research
Source: Yahoo! Finance
implanted mechanical circulatory support device, has the potential to improve the time in therapeutic range a factor correlated in the ARIES-HM3 trial with better patient outcomes PONTE VEDRA, Fla. June 3, 2024 /PRNewswire/ -- Cadrenal Therapeutics, Inc. , (Nasdaq: CVKD), a biopharmaceutical company developing tecarfarin, a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions, today highlighted a groundbreaking presentation at the International Society for Heart & Lung Transplantation (ISHLT) 44th Annual Meeting & Scientific Sessions. These new findings from secondary analyses of the ARIES-HM3 trial were released in a presentation titled, "Impact of Vitamin K Antagonist (VKA) Therapy On Outcomes In a Randomized Controlled Trial of Aspirin Removal In Left Ventricular Assist Device (LVAD) Patients - A Pre-Specified Analysis From the Aspirin and Hemo
Show less
Read more
Impact Snapshot
Event Time:
CVKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CVKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CVKD alerts
High impacting Cadrenal Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CVKD
News
- Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor ConferencePR Newswire
- Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD PatientsPR Newswire
- Cadrenal Therapeutics to Present at Upcoming Investor ConferencesPR Newswire
- Cadrenal Therapeutics, Inc. (CVKD): A New Penny Stock to Buy Now [Yahoo! Finance]Yahoo! Finance
- Cadrenal Therapeutics Provides Second Quarter 2024 Corporate UpdatePR Newswire
CVKD
Sec Filings
- 9/25/24 - Form 8-K
- 9/5/24 - Form 8-K
- 8/16/24 - Form 8-K
- CVKD's page on the SEC website